Skip to main content

Clinical trial INCAGN1876-201

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Cancers
Organ Multiples
Trial status Trial closed for recruitment
Investigator
Trial type
Interventionnal with IMP
Phase Trial phase 1
Academic trial Non
Sponsor Incyte Corporate
EudraCT Identifier 2016-004989-25
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03126110
Inclusion criteria second line RECIST 1.1 Biopsy
Last update